Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence
- PMID: 15677600
- DOI: 10.1176/appi.ajp.162.2.340
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence
Abstract
Objective: Physicians may prescribe buprenorphine for opioid agonist maintenance treatment outside of narcotic treatment programs, but treatment guidelines for patients with co-occurring cocaine and opioid dependence are not available. This study compares effects of buprenorphine and methadone and evaluates the efficacy of combining contingency management with maintenance treatment for patients with co-occurring cocaine and opioid dependence.
Method: Subjects with cocaine and opioid dependence (N=162) were provided manual-guided counseling and randomly assigned in a double-blind design to receive daily sublingual buprenorphine (12-16 mg) or methadone (65-85 mg p.o.) and to contingency management or performance feedback. Contingency management subjects received monetary vouchers for opioid- and cocaine-negative urine tests, which were conducted three times a week; voucher value escalated during the first 12 weeks for consecutive drug-free tests and was reduced to a nominal value in weeks 13-24. Performance feedback subjects received slips of paper indicating the urine test results. The primary outcome measures were the maximum number of consecutive weeks abstinent from illicit opioids and cocaine and the proportion of drug-free tests. Analytic models included two-by-two analysis of variance and mixed-model repeated-measures analysis of variance.
Results: Methadone-treated subjects remained in treatment significantly longer and achieved significantly longer periods of sustained abstinence and a greater proportion drug-free tests, compared with subjects who received buprenorphine. Subjects receiving contingency management achieved significantly longer periods of abstinence and a greater proportion drug-free tests during the period of escalating voucher value, compared with those who received performance feedback, but there were no significant differences between groups in these variables during the entire 24-week study.
Conclusions: Methadone may be superior to buprenorphine for maintenance treatment of patients with co-occurring cocaine and opioid dependence. Combining methadone or buprenorphine with contingency management may improve treatment outcome.
Comment in
-
Methadone plus contingency management or performance feedback reduces cocaine and opiate use in people with drug addiction.Evid Based Ment Health. 2005 Nov;8(4):112. doi: 10.1136/ebmh.8.4.112. Evid Based Ment Health. 2005. PMID: 16246888 No abstract available.
Similar articles
-
Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.Arch Gen Psychiatry. 2006 Feb;63(2):219-28. doi: 10.1001/archpsyc.63.2.219. Arch Gen Psychiatry. 2006. PMID: 16461866 Clinical Trial.
-
Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.Arch Gen Psychiatry. 1999 Sep;56(9):812-20. doi: 10.1001/archpsyc.56.9.812. Arch Gen Psychiatry. 1999. PMID: 12884887 Clinical Trial.
-
Comparison of buprenorphine and methadone in the treatment of opioid dependence.Am J Psychiatry. 1994 Jul;151(7):1025-30. doi: 10.1176/ajp.151.7.1025. Am J Psychiatry. 1994. PMID: 8010359 Clinical Trial.
-
Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials.Am J Drug Alcohol Abuse. 2009;35(5):339-49. doi: 10.1080/00952990903108215. Am J Drug Alcohol Abuse. 2009. PMID: 20180662
-
Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.Lancet Psychiatry. 2023 Jun;10(6):386-402. doi: 10.1016/S2215-0366(23)00095-0. Epub 2023 May 8. Lancet Psychiatry. 2023. PMID: 37167985
Cited by
-
The pharmacological treatment of opioid addiction--a clinical perspective.Eur J Clin Pharmacol. 2010 Jun;66(6):537-45. doi: 10.1007/s00228-010-0793-6. Epub 2010 Feb 19. Eur J Clin Pharmacol. 2010. PMID: 20169438 Review.
-
Differences in buprenorphine treatment quality across physician provider specialties.Drug Alcohol Depend. 2022 Aug 1;237:109510. doi: 10.1016/j.drugalcdep.2022.109510. Epub 2022 May 23. Drug Alcohol Depend. 2022. PMID: 35753279 Free PMC article.
-
Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.J Addict Res Ther. 2013 Apr 23;4(2):10.4172/2155-6105.1000146. doi: 10.4172/2155-6105.1000146. J Addict Res Ther. 2013. PMID: 24273683 Free PMC article.
-
Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses.PLoS One. 2020 Dec 28;15(12):e0244401. doi: 10.1371/journal.pone.0244401. eCollection 2020. PLoS One. 2020. PMID: 33370393 Free PMC article.
-
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.Drug Alcohol Depend. 2020 Nov 1;216:108193. doi: 10.1016/j.drugalcdep.2020.108193. Epub 2020 Aug 1. Drug Alcohol Depend. 2020. PMID: 32861136 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical